Rexahn Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board in Major Depressive Disorder
Published: Jul 06, 2010
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the formation of a scientific advisory board (SAB) in major depressive disorder (MDD). The SAB will actively collaborate with Rexahn on the clinical development of Serdaxin® for the treatment of MDD.